株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌ワクチンに関する各種提携契約:取引動向、企業、財務および予測

Global Cancer Vaccine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 233051
出版日 ページ情報 英文 190 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
癌ワクチンに関する各種提携契約:取引動向、企業、財務および予測 Global Cancer Vaccine Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日: 2016年10月06日 ページ情報: 英文 190 Pages
概要

当レポートでは、企業による癌ワクチンのパートナー取引の方法と理由について分析し、バイオ医薬品市場における癌ワクチン取引動向、主要取引、および補助薬・ドラッグデリバリー取引・アライアンスの分析、癌ワクチン取引構造の分析、癌ワクチン取引一覧などを提供しています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 癌ワクチンの取引動向

  • イントロダクション
  • 過去数年間における癌ワクチンの取引
  • 癌ワクチン提携に最も活発な企業/機関
  • 癌ワクチン提携:取引タイプ別
  • 癌ワクチン提携:治療領域別
  • 癌ワクチン提携に対する開示された金融条件
    • 取引総額
    • 前金支払額
    • 目標達成報奨金
    • ロイヤルティ料率

第3章 主要取引

  • イントロダクション
  • 主要な癌ワクチン取引:取引額別

第4章 癌ワクチンに最も積極的な取引企業

  • イントロダクション
  • 癌ワクチンに最も積極的な取引企業
  • 癌ワクチンに最も積極的な提携企業プロファイル

第5章 癌ワクチン契約取引の一覧

  • イントロダクション
  • 癌ワクチン契約取引の一覧

第6章 癌ワクチン契約:技術タイプ別

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連資料

付録

  • 付録1:ドラッグデリバリー契約(企業別A-Z)
  • 付録2:ドラッグデリバリー契約(開発ステージ別)
    • 創薬
    • 前臨床
    • フェーズ?
    • フェーズ?
    • フェーズ?
    • 規制
    • 上市
    • 処方
  • 付録3:ドラッグデリバリー契約(タイプ別)
    • 資産購入
    • 譲渡
    • 大手製薬会社のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同上市
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売
    • 株式購入
    • 評価
    • 譲与
    • ジョイントベンチャー
    • ライセンシング
    • 訴訟
    • 製造
    • マーケティング
    • 物質移動
    • オプション
    • プロモーション
    • 研究
    • 合意
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 契約解除
    • 保証
  • 付録4:癌ワクチン契約(治療分野別)
  • 付録5:契約タイプの定義

Wildwood Venturesについて

Current Partnering Current Agreements CurrentPartneringの発行タイトル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP22011

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 210 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Key benefits

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Terms and Agreements includes:

  • Trends in Cancer Vaccine dealmaking in the biopharma industry since 2010
  • Analysis of Cancer Vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Cancer Vaccine deals
  • Access to Cancer Vaccine contract documents
  • Leading Cancer Vaccine deals by value since 2010
  • Most active Cancer Vaccine dealmakers since 2010

In Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 210 Cancer Vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Cancer Vaccine Partnering 2010-2016 report provides the reader with the following key benefits:

  • In-depth understanding of Cancer Vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
  • Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
  • Identify most active Cancer Vaccine dealmakers since 2010
  • Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking

  • 2.1. Introduction
  • 2.2. Cancer Vaccine partnering over the years
  • 2.3. Most active Cancer Vaccine dealmakers
  • 2.4. Cancer Vaccine partnering by deal type
  • 2.5. Cancer Vaccine partnering by therapy area
  • 2.6. Deal terms for Cancer Vaccine partnering
  • 2.6.1 Cancer Vaccine partnering headline values
  • 2.6.2 Cancer Vaccine deal upfront payments7
  • 2.6.3 Cancer Vaccine deal milestone payments
  • 2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals

  • 3.1. Introduction
  • 3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers

  • 4.1. Introduction
  • 4.2. Most active Cancer Vaccine dealmakers
  • 4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Vaccine deals by company A-Z

Appendix 2 - Cancer Vaccine deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Cancer Vaccine deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Cancer Vaccine partnering since 2010
  • Figure 2: Active Cancer Vaccine dealmaking activity- 2010 to 2016
  • Figure 3: Cancer Vaccine partnering by deal type since 2010
  • Figure 4: Cancer Vaccine partnering by disease type since 2010
  • Figure 5: Cancer Vaccine deals with a headline value
  • Figure 6: Cancer Vaccine deals with an upfront value
  • Figure 7: Cancer Vaccine deals with a milestone value
  • Figure 8: Cancer Vaccine deals with a royalty rate value
  • Figure 9: Top Cancer Vaccine deals by value since 2010
  • Figure 10: Most active Cancer Vaccine dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top